A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adrenocortical carcinoma; Genitourinary disorders; Penile cancer; Prostate cancer; Tumours
- Focus Therapeutic Use
- 28 Dec 2017 Status changed from not yet recruiting to recruiting.
- 08 Dec 2017 Planned initiation date changed from 30 Nov 2017 to 30 Jan 2018.
- 09 Nov 2017 New trial record